Compliance with antimicrobials de-escalation in septic patients and mortality rates

an old subject revisited

  • Jamal Wadi Al Ramahi M.D, FIDSA Office 11, The Medical Center, Jordan Hospital and medical Center. 29 Adeeb Wahbeh StreetAmman - Jordan 11118
  • Omran Abu Khalaf
  • Lamya Abu Shanab
  • Mohammad Obaidat Pharm
  • Maha Al Hasan
  • Mohammed Mhanna
  • Maha Hashim Abdulghani



To compare the recent de-escalations rates with a six-year earlier study, and mortality associated with de-escalation.



A prospective multicenter study including septic patients, all were on broad-spectrum antimicrobials (BSA). Excluded from the study patients on antimicrobial prophylaxis, and patients without a microbiological diagnosis, or bacteria were solely BSA-susceptible. The study team made recommendations for antimicrobials de-escalation to the treating physician(s) must an opportunity loomed.


182 patients were available for analysis. De-escalation was achieved in 43 (24%) patients. The clinical diagnoses, comorbidities, commonly used antimicrobials, the microbiological diagnoses were not different between the two groups (patients with and without de-escalation). Logistic regression analysis showed no correlation between bacterial species and de-escalation (Nagelkerke R2 = 0.076). Relapsing sepsis and reinfection were not different (P > 0.05). The in-hospital mortality rates for the de-escalated patients were lower (P = 0.015), not on day 30 (P = 0.354). The length of the ICU stay and ward stay were not different (P >0.05), but more de-escalated patients were discharged home from the ICU (P = 0.034), however, patients without de-escalation were discharged more from the ward (P = 0.002).


De-escalation rates increased within six years from 6.7% - 24% (P = 0.000), with added benefits of shorter ICU stay and less in-hospital mortality

Sep 15, 2019
How to Cite
WADI AL RAMAHI M.D, FIDSA, Jamal et al. Compliance with antimicrobials de-escalation in septic patients and mortality rates. The International Arabic Journal of Antimicrobial Agents, [S.l.], v. 9, n. 3, sep. 2019. ISSN 2174-9094. Available at: <>. Date accessed: 25 jan. 2021. doi: